NCT00914030

Brief Summary

The aim of the protocol is to better understand the impairments in visual processing, as such impairments may induce social interaction difficulties in subjects with autism spectrum disorders (adults and children) and schizophrenia, like face exploration.The same protocol will be used for the three populations, each population being compared with matched controls. The explorations are designed to test two different hypotheses regarding the mechanisms of the visual perception difficulties of the two populations. Even though difficulties to extract the global form of objects have been described in both subjects with autism and schizophrenia, we will test two different hypotheses for the two populations. We will test the hypothesis that subjects with autism display an advantage for the processing of local information arising at an early level of processing, whereas disorders observed in patients with schizophrenia originate from attention disorders. The protocol includes three consecutive studies, each one being applied in each of the three populations.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
140

participants targeted

Target at P50-P75 for all trials

Timeline
Completed

Started Jun 2009

Longer than P75 for all trials

Geographic Reach
1 country

5 active sites

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

June 1, 2009

Completed
1 day until next milestone

First Submitted

Initial submission to the registry

June 2, 2009

Completed
2 days until next milestone

First Posted

Study publicly available on registry

June 4, 2009

Completed
7.5 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 1, 2016

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

December 1, 2016

Completed
Last Updated

August 26, 2016

Status Verified

August 1, 2016

Enrollment Period

7.5 years

First QC Date

June 2, 2009

Last Update Submit

August 25, 2016

Conditions

Autism Spectrum DisordersSchizophrenia

Keywords

Visual perceptionLocal/global processingAttentionVisual primingCollinearityGrouping

Study Arms (6)

A1

Patients with schizophrenia

Other: Neuropsychological evaluation

A2

Control subjects matched individually with patients with schizophrenia

Other: Neuropsychological evaluation

B1

Adult subjects with autism

Other: Neuropsychological evaluation

B2

Control subjects matched individually with adult subjects with autism

Other: Neuropsychological evaluation

C1

Children with autism

Other: Neuropsychological evaluation

C2

Control subjects matched individually with children with autism

Other: Neuropsychological evaluation

Interventions

Neuropsychological evaluationOTHER

Study one: global/local processing, with a neutral prime (stimulus influencing the processing of the subsequent stimulus)Study two: global/ local processing with a prime whose elements are collinear.Study three: global/local processing with a prime whose elements are not collinear

Also known as: Each study will be conducted successively in each group (A1/ A2, B1/B2, C1/C2).
A1A2B1B2C1C2

Eligibility Criteria

Age7 Years - 55 Years
Sexall
Healthy VolunteersYes
Age GroupsChild (0-17), Adult (18-64)
Sampling MethodNon-Probability Sample
Study Population

Psychiatry clinic in Strasbourg and Brumath. Pedopsychiatry Clinic in Strasbourg. Residents of Strasbourg and Brumath

You may qualify if:

  • IQ above 70, as evaluated with the WAIS III in adults and with the WISC in children
  • signed consent
  • DSM IV criteria in case of autism spectrum disorders or schizophrenia

You may not qualify if:

  • grave or non stabilized somatic pathology
  • pathology affecting the central nervous system; other than the studied pathologies
  • intake of psychotropic drug, except for patients
  • invalidating sensory processes

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (5)

Pôle départemental du Centre de Ressources Autisme pour adultes (67) - Etablissement public de santé Alsace-Nord (site de Brumath)

Brumath, 67170, France

RECRUITING

Centre de Ressources Autisme Pôle adultes (68) - Espace Autisme 68

Colmar, 68000, France

RECRUITING

Clinique Lautréamont

Loos, 59120, France

RECRUITING

Pôle régional du Centre de Ressources Autisme pour enfants et adolescents - Unité d'évaluation des troubles du développement Hôpital de l'Elsau - Pôle de Psychiatrie - Unité d'évaluation des troubles du développement Hôpital de l'Elsau - HUS

Strasbourg, 67000, France

RECRUITING

INSERM U666 ; Pôle de Psychiatrie - Service de Psychiatrie Adulte- HUS

Strasbourg, 67091, France

RECRUITING

MeSH Terms

Conditions

Autism Spectrum DisorderSchizophrenia

Condition Hierarchy (Ancestors)

Child Development Disorders, PervasiveNeurodevelopmental DisordersMental DisordersSchizophrenia Spectrum and Other Psychotic Disorders

Study Officials

  • Anne GIERSCH

    Institut National de la Santé Et de la Recherche Médicale, France

    PRINCIPAL INVESTIGATOR

Central Study Contacts

GIERSCH Anne, MD

CONTACT

giersch@unistra.fr

Study Design

Study Type
observational
Observational Model
CASE CONTROL
Time Perspective
CROSS SECTIONAL
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

June 2, 2009

First Posted

June 4, 2009

Study Start

June 1, 2009

Primary Completion

December 1, 2016

Study Completion

December 1, 2016

Last Updated

August 26, 2016

Record last verified: 2016-08

Locations

FR(5)